Teva Pharmaceutical Industries Ltd. priced a senior notes offering totaling approximately $4.9 billion. The issuance includes multiple tranches denominated in U.S. dollars and Euros. These notes feature maturity dates ranging from 2032 to 2037.
Teva will use the proceeds and cash on hand to redeem existing senior notes with higher interest rates. This refinancing move aims to lower the company's total debt costs and improve its balance sheet. Settlement is scheduled for approximately September 16, 2026.